Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.58 |
| ▸ | JAK3 | P52333 | 2/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.56 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.56 |
| ▸ | JAK1 | P23458 | 4/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059873 | 0.89 | CDK19 (0.58) | JAK2JAK3ALKCDK19JAK1 | |
| SCHEMBL24258131 | 0.88 | TNK2 (0.53) | JAK2JAK3ALKCDK19TNK2 | |
| SCHEMBL24258129 | 0.88 | JAK3 (0.65) | JAK2JAK3JAK1TNK2TYK2 | |
| SCHEMBL24258095 | 0.86 | JAK3 (0.57) | JAK2JAK3ALKJAK1KDR | |
| SCHEMBL26361468 | 0.85 | JAK3 (0.60) | JAK2JAK3JAK1TNK2TYK2 | |
| SCHEMBL22261399 | 0.84 | JAK3 (0.81) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL15060022 | 0.83 | JAK1 (0.58) | JAK2JAK3ALKCDK19JAK1 | |
| SCHEMBL24258132 | 0.83 | IRAK1 (0.51) | JAK2JAK3ALKTNK2CHEK1 | |
| Hydrochloric Acid SCHEMBL15059314 | 0.82 | JAK1 (0.57) | JAK2JAK3ALKCDK19JAK1 | |
| SCHEMBL26361851 | 0.82 | LRRK2 (0.53) | JAK2ALKTNK2CHEK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | claimed |
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-28 | — | — | US | disclosed |
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH | 2023-09-28 | — | — | US | disclosed |
| WO-2022036310-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013092854-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303499-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNK2, TNNI3K | JAK2 604/4885JAK3 500/4885ALK 272/4885 |
| US-20150005281-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885ALK 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.